Monash IVF Group Ltd (ASX: MVF) Share Price and News

Price

$0.75

Movement

0.04 (+5.63%)

as at 15 Apr 12:53pm (20 mins delayed)

52 Week Range

$0.68 - $1.53

 
1 Year Return

-47.92%

Monash IVF Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $276.64 million
P/E Ratio 20.32
Dividend Yield 7.39%
Shares Outstanding 389.63 million
Earnings per share -0.007
Dividend per share 0.05
Year To Date Return -43.62%
Earnings Yield 4.92%
Franking 100%
Share Price

$0.75

Day Change

0.04 (+5.63%)

52 Week Range

$0.68 - $1.53

Yesterday's Close

$0.71

Today's Open

$0.72

Days Range

$0.71 - $0.755

Volume

12,483,864

Avg. Volume (1 month)

2,662,663

Turnover

$8,986,678

as at 15 Apr 12:53pm

Monash IVF Group Ltd (ASX: MVF)
Latest News

Two young children wearing caps poke their heads above a wall with a panoramic view of a lush countryside behind them.
52-Week Highs

2 ASX small-cap shares breaking multi-year highs today

It's a big day for these small stocks on Wednesday.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

The Monash IVF (ASX:MVF) share price is gaining 6% today. Here's why

The company appears to be benefiting from Victoria lifting a ban on IVF treatments.

Read more »

A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.
Investing Strategies

4 ASX shares tipped for buybacks in 2022: expert

Here are a few companies that might give some money back to shareholders next year, according to Allan Gray's Suhas…

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Post-COVID baby boom? That could supercharge this ASX share

Birth rates always climb after terrible global events. This stock could benefit as Australia looks to life after the coronavirus…

Read more »

ASX shares Business man marking buy on board and underlining it
Broker Notes

2 ASX shares that are rated as buys by multiple brokers

Monash IVF is one of the ASX shares that brokers like at the moment.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Earnings Results

Monash IVF (ASX:MVF) share price up 3% on guidance beating profits

The ASX healthcare share delivered its full year financial results this morning.

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Share Market News

2 ASX shares that many brokers think could be buys

Credit Corp and Monash IVF are two ASX shares that a few brokers like.

Read more »

A smiling woman with a handful of $100 notes, indicating strong dividend payments
Dividend Investing

Top brokers name 2 ASX dividend shares to buy today

Here are two dividend shares brokers have named as buys...

Read more »

ASX healthcare digital disruption woman has medical consultation appointment video video call with her doctor.
Healthcare Shares

ASX healthcare shares could be next to be hit by the digital disruption

You might think ASX healthcare shares would be among the most insulated from the digital disruption, but that view doesn’t…

Read more »

Share Gainers

Monash IVF (ASX:MVF) share price jumps on profit growth and dividend restart

The Monash IVF Group Ltd (ASX: MVF) share price is bucking the market downtrend after it posted its profit results…

Read more »

Share Fallers

Why Costa, Monash IVF, Newcrest, & Xero shares are dropping lower

Costa Group Holdings Ltd (ASX:CGC) and Newcrest Mining Ltd (ASX:NCM) shares are two of four dropping lower on Monday...

Read more »

Share Fallers

Why BetMakers, Flight Centre, Monash IVF, & Sydney Airport are dropping lower

Flight Centre Travel Group Ltd (ASX:FLT) and Monash IVF Group Ltd (ASX:MVF) shares are two of four dropping lower today...

Read more »

Frequently Asked Questions

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
06 Mar 2025 $0.0260 100.00% Interim 11 Apr 2025
05 Sep 2024 $0.0250 100.00% Final 11 Oct 2024
07 Mar 2024 $0.0250 100.00% Interim 05 Apr 2024
07 Sep 2023 $0.0220 100.00% Final 11 Oct 2023
08 Mar 2023 $0.0220 100.00% Interim 06 Apr 2023
08 Sep 2022 $0.0220 100.00% Final 07 Oct 2022
07 Mar 2022 $0.0220 100.00% Interim 04 Apr 2022
09 Sep 2021 $0.0210 100.00% Final 08 Oct 2021
09 Mar 2021 $0.0210 100.00% Interim 07 Apr 2021
05 Mar 2020 $0.0210 100.00% Interim 02 Oct 2020
05 Sep 2019 $0.0300 100.00% Final 11 Oct 2019
06 Sep 2018 $0.0260 100.00% Final 12 Oct 2018
08 Mar 2018 $0.0340 100.00% Interim 06 Apr 2018
06 Sep 2017 $0.0000 100.00% Final 13 Oct 2017
02 Mar 2017 $0.0430 100.00% Interim 07 Apr 2017
06 Sep 2016 $0.0450 100.00% Final 14 Oct 2016
08 Mar 2016 $0.0400 100.00% Interim 08 Apr 2016

MVF ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Monash IVF Group Ltd

Monash IVF Group Ltd (ASX: MVF) is a specialist assisted reproductive services provider. The company offers fertility treatments and specialist diagnostic obstetric and gynaecological ultrasound services. Monash is among the leading providers of assisted reproductive services in Australia and Malaysia. It also has a cooperative agreement with a hospital in China. 

MVF Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
11 Apr 2025 $0.69 $-0.39 -36.28% 16,586,104 $0.90 $0.90 $0.69
10 Apr 2025 $1.08 $0.02 1.90% 480,474 $1.12 $1.12 $1.08
09 Apr 2025 $1.06 $-0.02 -1.86% 1,937,471 $1.06 $1.08 $1.05
08 Apr 2025 $1.08 $0.04 3.86% 644,725 $1.03 $1.08 $1.03
07 Apr 2025 $1.04 $-0.02 -1.90% 1,453,657 $1.02 $1.04 $1.00
04 Apr 2025 $1.06 $-0.03 -2.78% 1,042,734 $1.07 $1.07 $1.04
03 Apr 2025 $1.08 $-0.02 -1.81% 730,446 $1.09 $1.10 $1.07
02 Apr 2025 $1.11 $-0.02 -1.79% 1,204,995 $1.12 $1.13 $1.07
01 Apr 2025 $1.12 $-0.01 -0.88% 338,582 $1.13 $1.14 $1.12
31 Mar 2025 $1.14 $0.02 1.79% 4,261,721 $1.11 $1.14 $1.11
28 Mar 2025 $1.12 $0.00 0.00% 571,441 $1.11 $1.13 $1.11
27 Mar 2025 $1.11 $0.03 2.78% 1,106,080 $1.09 $1.12 $1.07
26 Mar 2025 $1.08 $-0.01 -0.92% 570,576 $1.11 $1.11 $1.07
25 Mar 2025 $1.09 $-0.01 -0.91% 1,337,580 $1.10 $1.11 $1.08
24 Mar 2025 $1.10 $0.00 0.00% 1,146,077 $1.12 $1.12 $1.08
21 Mar 2025 $1.10 $-0.03 -2.65% 2,268,923 $1.13 $1.13 $1.10
20 Mar 2025 $1.13 $0.00 0.00% 484,334 $1.13 $1.14 $1.12
19 Mar 2025 $1.13 $-0.01 -0.88% 752,163 $1.14 $1.14 $1.11
18 Mar 2025 $1.14 $-0.02 -1.73% 780,371 $1.16 $1.17 $1.14
17 Mar 2025 $1.16 $0.02 1.75% 157,667 $1.16 $1.16 $1.14

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Dec 2024 Michael Knaap Issued 614,447 $761,914
Issue of securities. 1,664,479 Rights
31 Oct 2024 Josef Czyzewski Transfer 19,101 $22,443
Off-market transfer. Assuming off market transfer of shares
31 Oct 2024 Josef Czyzewski Transfer 19,101 $22,443
Off-market transfer. Assuming off market transfer of shares
16 Sep 2024 Catherine (Cathy) Aston Buy 75,000 $90,847
On-market trade.
16 Sep 2024 Catherine (Cathy) Aston Buy 2,000 $2,422
On-market trade.
13 Sep 2024 Michael Knaap Exercise 466,166 $550,075
Conversion of securities. 1,050,032 Rights
13 Sep 2024 Michael Knaap Buy 157,317 $185,634
Conversion of securities.
17 Apr 2024 Michael Knaap Exercise 501,629 $722,345
Conversion of securities. 1,516,198 Rights
17 Apr 2024 Michael Knaap Issued 501,629 $722,345
Conversion of securities.
17 Apr 2024 Michael Knaap Issued 75,696 $109,002
Dividend Reinvestment Plan (DRP).
17 Apr 2024 Michael Knaap Exercise 501,629 $722,345
Conversion of securities. 1,516,198 Rights
17 Apr 2024 Michael Knaap Buy 577,325 $831,348
Conversion of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Zita Peach Non-Executive Director Oct 2016
Ms Peach has more than 25 years of commercial experience in the pharmaceutical, biotechnology, medical devices and health services industries, and has worked for industry players such as CSL Limited, Fresenius Kabi and Merck Sharp & Dohme, the Australian subsidiary of Merck Inc. Zita is currently a Non-Executive Director of three private equity owned companies, Icon Group Pty Ltd, VetPartners Pty Ltd and Nucleus Network Pty Ltd. Zita is also the Chair of the Olivia Newton John Cancer Research Institute. Former directorships (last 3 years): Starpharma Holdings Limited.
Mr Richard Hugh Davis Non-Executive ChairmanNon-Executive Director Jun 2014
Mr. Davis worked for InvoCare for 20 years until 2008. For the majority of that time he held the position of CEO and managed the growth of that business through a number of ownership changes and over 20 acquisitions, including offshore in Singapore. Prior to InvoCare Limited, Richard worked as an accounting partner of Bird Cameron. He is member of risk committee.
Mr Neil John Broekhuizen Non-Executive Director Jun 2014
Mr. Broekhuizen is the Joint Chief Executive Officer of Ironbridge. Neil has over 30 years' experience in the finance industry including 28 years in private equity with Investcorp and Bridgepoint in Europe and Ironbridge in Australia. He has sat on the Ironbridge Investment Committee since inception. Former directorships (last 3 years): Bravura Solutions Limited. He is member of Risk Committee.
Mr Michael Damian Knaap Chief Executive OfficerManaging Director Sep 2015
Mr Knaap has 30 years of experience in executive positions with a financial, operational, strategic and leadership background in Healthcare and FMCG industries. Prior to joining MVF Group, Michael was with Patties Foods Limited where he held a number of executive positions over six years, including the role of Chief Financial Officer and Company Secretary.
Dr Richard Charles Henshaw Executive Director Apr 2014
Dr Henshaw MD FRANZCOG FRCOG has practiced in the field of reproductive medicine since 1995. Richard works as a Fertility Specialist for the Group. Richard has served on many national bodies, including RANZCOG Council, the IVF Medical Directors Group of Australia and New Zealand, and the Reproductive Technology Accreditation Committee.
Ms Catherine Jane West Non-Executive Director Sep 2020
Ms West has over 25 years of legal, business affairs and strategy experience in customer focused businesses in the media, entertainment, telecommunications and medical sectors in Australia, the United Kingdom and Europe. Catherine is Non Executive Director of Peter Warren Automotive Group. In addition, she is Chair of the National Institute of Dramatic Art (NIDA), a Director of the NIDA Foundation and Chair of the Board of Governors of Wenona School. Catherine was also until recently, a Director of the Sydney Breast Cancer Foundation Limited until her resignation on 30th June 2024. She formerly held directorship with Endeavour Group.
Ms Catherine (Cathy) Ann Aston Non-Executive Director Feb 2024
Ms. Catherine Aston is an experienced Non-Executive Director / Chair of listed and unlisted entities covering technology, financial services, marketing services, health and government sectors across Australia and Asia. Catherine has a commercial background with executive roles in finance, marketing and strategy, including as CFO for Telstra International and Chief Executive Officer of a mobiles joint venture in Sri Lanka. Catherine is currently a Non Executive Director of Macquarie Investment Management Ltd (Chair of the Audit, Risk and Compliance committee), IVE Group Ltd (Chair of the Audit and Risk Committee) and IMB Bank Ltd (Chair). Catherine's advisory roles have included work with the NSW State Government and serving as an advisory board member of Avanseus Pty Ltd, a Singapore based AI business. Former directorships (last 3 years): Virtus Health Ltd, Integrated Research Ltd, Over the Wire Ltd.
Mr Malik Jainudeen Chief Financial OfficerCompany Secretary Apr 2019
-
Jan Lagerwij Asia Managing Director
-
Malik Jainudeen Chief Financial OfficerCompany Secretary
-
Tedd Fuell Chief Governance & Risk Officer
-
Thierry Panthier Chief Information Officer
-
Fiona Allen Chief Marketing Officer
-
Hamish Hamilton Chief Operating Officer
-
Peggy North Chief People & Culture Officer
-
Deirdre Zander Fox Chief Scientific Officer
-
Sloane Karlson General Manager Projects
-
Prof Luk Rombauts Group Medical Director
-
Sarah Bollom Regional Donor & Surrogacy Manager
-
Monique Teodoro Regional Manager Day Surgeries
-
Rebecca Redden Regional Manager for Ultrasound SA/NT and Genetics
-
Claire Ellem Regional Manager QLD
-
Nicolette Curtis Regional Manager VIC & NSW
-
Kate Robertson Regional Manager WA
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 82,222,688 21.10%
Citicorp Nominees Pty Limited 67,647,801 17.36%
J P Morgan Nominees Australia Pty Limited 64,131,568 16.46%
Argo Investments Limited 20,292,940 5.21%
Washington H Soul Pattison And Company Limited 18,675,000 4.79%
Bnp Paribas Nominees Pty Ltd 9,120,255 2.34%
Palm Beach Nominees Pty Ltd 7,813,727 2.01%
Ubs Nominees Pty Ltd 6,645,317 1.71%
HSBC Custody Nominees (Australia) Limited A/C 2 3,648,216 0.94%
Neweconomy Com Au Nominees Pty Limited 3,473,430 0.89%
National Nominees Limited 3,376,384 0.87%
Pacific Custodians Pty Limted 2,579,603 0.66%
Ippoliti Pty Ltd 2,245,945 0.58%
Mr Prashant Nadkarni 2,011,336 0.52%
Vollenhoven Investments Pty Ltd 1,461,484 0.38%
Mclachlan Future Fund Pty Ltd 1,447,787 0.37%
Ong Administration Pty Ltd 1,300,000 0.33%
BNP Paribas Nominees Pty Ltd i 1,201,906 0.31%
Dalyne Pty Ltd 1,172,933 0.30%
Citicorp Nominees Pty Limited i 1,170,000 0.30%

Profile

since

Note